--- title: "ZeZentalis Pharma | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286151877.md" datetime: "2026-05-12T20:21:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286151877.md) - [en](https://longbridge.com/en/news/286151877.md) - [zh-HK](https://longbridge.com/zh-HK/news/286151877.md) --- # ZeZentalis Pharma | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.5, missing the estimate of USD -0.4725. Zentalis Pharmaceuticals, Inc. operates as a single segment, therefore, all financial and operational metrics are reported on a consolidated basis . #### Operational Metrics - **Net Loss**: For the three months ended March 31, 2026, the net loss was - $35.4 million, an improvement from - $48.3 million for the three months ended March 31, 2025. The accumulated deficit as of March 31, 2026, was - $1.2 billion . - **Research and Development Expenses**: These expenses increased to $28.7 million for the three months ended March 31, 2026, from $27.2 million for the same period in 2025. This $1.5 million increase was primarily due to a $6.8 million rise in clinical expenses and drug manufacturing for the DENALI and ASPENOVA trials, partially offset by a $3.9 million decrease in personnel expense (including - $1.2 million in non-cash stock-based compensation), a $1.2 million decrease from a one-time impairment charge in Q1 2025, and a $0.2 million decrease in allocated overhead . - **General and Administrative Expenses**: These expenses decreased to $9.1 million for the three months ended March 31, 2026, from $10.6 million for the same period in 2025. This - $1.5 million decrease was mainly due to a - $2.0 million reduction in personnel expense (including - $1.2 million in non-cash stock-based compensation), partially offset by a $0.5 million increase in consulting, outside services, and other allocated costs . - **Restructuring Expenses**: These expenses were - $0 for the three months ended March 31, 2026, compared to $7.8 million for the same period in 2025, following a corporate restructuring announced on January 28, 2025, which reduced the workforce by approximately 40% . - **Total Operating Expenses**: Total operating expenses were $37.855 million for the three months ended March 31, 2026, compared to $45.623 million for the three months ended March 31, 2025 . - **Investment and Other Income (Expense), Net**: This category showed an income of $2.6 million for the three months ended March 31, 2026, a significant increase from an expense of - $2.7 million for the same period in 2025. This $5.3 million increase was primarily due to a - $7.0 million non-cash recognized loss on mark-to-market adjustment for equity securities in Q1 2025, partially offset by a - $1.7 million decrease in returns on invested cash and marketable debt securities . #### Cash Flow - **Net Cash Used in Operating Activities**: - $33.0 million for the three months ended March 31, 2026, compared to - $32.6 million for the same period in 2025 . - **Net Cash Provided by Investing Activities**: $30.0 million for the three months ended March 31, 2026, primarily from $60.0 million in proceeds from maturities of marketable securities, offset by - $30.0 million in net investment of excess cash. This was lower than the $40.5 million provided in the same period in 2025 . - **Net Cash Used in Financing Activities**: - $1.1 million for the three months ended March 31, 2026, primarily due to - $1.4 million used for net-settlement of restricted stock unit vesting, partially offset by $0.3 million from common stock issuance under equity incentive plans. This compares to $189 thousand provided by financing activities in the same period in 2025 . #### Liquidity and Outlook As of March 31, 2026, Zentalis Pharmaceuticals, Inc. had $211.8 million in cash, cash equivalents, and marketable securities, which are anticipated to cover operating expenses and capital expenditure requirements into late 2027 . The company expects to complete enrollment in all cohorts of the DENALI Part 2 trial and release topline data by year-end 2026 . Zentalis Pharmaceuticals, Inc. will require substantial additional capital to fund ongoing operations and its growth strategy, with - $69.5 million of common stock remaining available for sale under its At-The-Market (ATM) program as of March 31, 2026 . ### Related Stocks - [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [OceanPal Inc. Announces 2026 Annual General Meeting of Shareholders to be Held on June 16, 2026 | SVRN Stock News](https://longbridge.com/en/news/286308382.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)